Characteristics and outcomes of small bowel adenocarcinoma: 14 years of experience at a single tertiary hospital in Saudi Arabia

Alshamsan,Bader; Aseafan,Mohamed; Badran,Ahmed; Shaheen,Amgad; Elshenawy,Mahmoud A.; Bazarbashi,Shouki; Aljubran,Ali H.

doi:10.3892/mco.2023.2613

Characteristics and outcomes of small bowel adenocarcinoma: 14 years of experience at a single tertiary hospital in Saudi Arabia

Authors:
- Bader Alshamsan
- Mohamed Aseafan
- Ahmed Badran
- Amgad Shaheen
- Mahmoud A. Elshenawy
- Shouki Bazarbashi
- Ali H. Aljubran
View Affiliations

Affiliations: Section of Medical Oncology, Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia
Published online on: January 27, 2023 https://doi.org/10.3892/mco.2023.2613
Article Number: 17
Copyright: © Alshamsan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Small bowel adenocarcinoma (SBA) is an extremely rare cancer type. In the present study, the patient characteristics and clinical outcomes of patients diagnosed and treated for SBA at a single tertiary hospital were reported. All patients diagnosed and managed between 2007 and 2020 were reviewed. Regression analysis was used to assess variables associated with the metastatic stage at diagnosis. The Kaplan‑Meier method was used to estimate survival and the log‑rank test was used to determine factors associated with survival outcomes. Out of 137 cases of small bowel primary tumor, 43 consecutive patients with SBA were diagnosed with a median age of 53 years and the majority (76.7%) were males. The common initial presenting symptoms were abdominal pain (58.8%) and bowel obstruction (30.2%). The most common primary site was the duodenum (60.5%) and the majority (65.1%) were diagnosed with stage III/IV disease. Patients with a high neutrophil‑lymphocyte ratio (NLR) (≥0.85) were more likely to be in the metastatic stage at diagnosis (P=0.01). The 3‑year overall survival (OS) rates based on stage were 100% (I), 85% (II), 53% (III) and 33.9% (IV) (P=0.001). In addition to the stage, the Eastern Cooperative Oncology Group Performance Status (P<0.001), NLR (P<0.001), hypoalbuminemia (P=0.02) and chemotherapy in a metastatic setting (P=0.02) were prognostic factors for OS. In conclusion, NLR is a potential prognostic biomarker for a metastatic stage at diagnosis. Advanced stage, lower performance status score, low albumin level and high NLR are associated with short OS.

View Figures

View References

1	Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022.PubMed/NCBI View Article : Google Scholar
2	Lepage C, Bouvier AM, Manfredi S, Dancourt V and Faivre J: Incidence and management of primary malignant small bowel cancers: A well-defined French population study. Am J Gastroenterol. 101:2826–2832. 2006.PubMed/NCBI View Article : Google Scholar
3	Bilimoria KY, Bentrem DJ, Wayne JD, Ko CY, Bennett CL and Talamonti MS: Small bowel cancer in the United States: Changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg. 249:63–71. 2009.PubMed/NCBI View Article : Google Scholar
4	Schottenfeld D, Beebe-Dimmer JL and Vigneau FD: The epidemiology and pathogenesis of neoplasia in the small intestine. Ann Epidemiol. 19:58–69. 2009.PubMed/NCBI View Article : Google Scholar
5	Barsouk A, Rawla P, Barsouk A and Thandra KC: Epidemiology of cancers of the small intestine: Trends, risk factors, and prevention. Med Sci (Basel). 7(46)2019.PubMed/NCBI View Article : Google Scholar
6	Dabaja BS, Suki D, Pro B, Bonnen M and Ajani J: Adenocarcinoma of the small bowel: Presentation, prognostic factors, and outcome of 217 patients. Cancer. 101:518–526. 2004.PubMed/NCBI View Article : Google Scholar
7	Moon YW, Rha SY, Shin SJ, Chang H, Shim HS and Roh JK: Adenocarcinoma of the small bowel at a single Korean institute: Management and prognosticators. J Cancer Res Clin Oncol. 136:387–394. 2010.PubMed/NCBI View Article : Google Scholar
8	Aparicio T, Zaanan A, Svrcek M, Laurent-Puig P, Carrere N, Manfredi S, Locher C and Afchain P: Small bowel adenocarcinoma: Epidemiology, risk factors, diagnosis and treatment. Dig Liver Dis. 46:97–104. 2014.PubMed/NCBI View Article : Google Scholar
9	Colina A, Hwang H, Wang H, Katz MHG, Sun R, Lee JE, Thomas J, Tzeng CW, Wolff RA, Raghav K and Overman MJ: Natural history and prognostic factors for localised small bowel adenocarcinoma. ESMO Open. 5(e000960)2020.PubMed/NCBI View Article : Google Scholar
10	Lech G, Korcz W, Kowalczyk E, Słotwiński R and Słodkowski M: Primary small bowel adenocarcinoma: Current view on clinical features, risk and prognostic factors, treatment and outcome. Scand J Gastroenterol. 52:1194–1202. 2017.PubMed/NCBI View Article : Google Scholar
11	Overman MJ: Recent advances in the management of adenocarcinoma of the small intestine. Gastrointest Cancer Res. 3:90–96. 2009.PubMed/NCBI
12	Hong SH, Koh YH, Rho SY, Byun JH, Oh ST, Im KW, Kim EK and Chang SK: Primary adenocarcinoma of the small intestine: Presentation, prognostic factors and clinical outcome. Jpn J Clin Oncol. 39:54–61. 2009.PubMed/NCBI View Article : Google Scholar
13	Yanko E, Le D, Mahmood S, Ginther DN, Chalchal HI, Kanthan R, Haider K, Zaidi A, Dueck DA, Ahmed O, et al: Outcomes of patients with small intestine adenocarcinoma in a canadian province: A retrospective multi-center population-based cohort study. Cancers (Basel). 14(2581)2002.PubMed/NCBI View Article : Google Scholar
14	Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, McLeod L, Delacqua G, Delacqua F, Kirby J, et al: The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 95(103208)2019.PubMed/NCBI View Article : Google Scholar
15	Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N and Conde JG: Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 42:377–381. 2009.PubMed/NCBI View Article : Google Scholar
16	Conill C, Verger E and Salamero M: Performance status assessment in cancer patients. Cancer. 65:1864–1866. 1990.PubMed/NCBI View Article : Google Scholar
17	Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and Winchester DP: The eighth edition AJCC cancer staging manual: Continuing to build a bridge from a population-based to a more ‘personalized’ approach to cancer staging. CA Cancer J Clin. 67:93–99. 2017.PubMed/NCBI View Article : Google Scholar
18	Schwartz LH, Litière S, De Vries E, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, et al: RECIST 1.1-update and clarification: From the RECIST committee. Eur J Cancer. 62:132–137. 2016.PubMed/NCBI View Article : Google Scholar
19	Badora-Rybicka A, Nowara E and Starzyczny-Słota D: Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio before chemotherapy as potential prognostic factors in patients with newly diagnosed epithelial ovarian cancer. ESMO Open. 1(e000039)2016.PubMed/NCBI View Article : Google Scholar
20	Noh H, Eomm M and Han A: Usefulness of pretreatment neutrophil to lymphocyte ratio in predicting disease-specific survival in breast cancer patients. J Breast Cancer. 16:55–59. 2013.PubMed/NCBI View Article : Google Scholar
21	Wang D, Li C, Li Y, Liu W, Zhao L, Güngör C, Tan F and Zhou Y: Specific survival nomograms based on SEER database for small intestine adenocarcinoma. Ann Palliat Med. 10:7440–7457. 2021.PubMed/NCBI View Article : Google Scholar
22	Tsushima T, Taguri M, Honma Y, Takahashi H, Ueda S, Nishina T, Kawai H, Kato S, Suenaga M, Tamura F, et al: Multicenter retrospective study of 132 patients with unresectable small bowel adenocarcinoma treated with chemotherapy. Oncologist. 17:1163–1170. 2012.PubMed/NCBI View Article : Google Scholar
23	Gu Y, Deng H, Wang D and Li Y: Metastasis pattern and survival analysis in primary small bowel adenocarcinoma: A SEER-based study. Front Surg. 8(759162)2021.PubMed/NCBI View Article : Google Scholar
24	Negoi I, Paun S, Hostiuc S, Stoica B, Tanase I, Negoi RI and Beuran M: Most small bowel cancers are revealed by a complication. Einstein (Sao Paulo). 13:500–505. 2015.PubMed/NCBI View Article : Google Scholar : (In English, Portuguese).
25	Chaiyasate K, Jain AK, Cheung LY, Jacobs MJ and Mittal VK: Prognostic factors in primary adenocarcinoma of the small intestine: 13-Year single institution experience. World J Surg Oncol. 6(12)2008.PubMed/NCBI View Article : Google Scholar
26	Farhat MH, Shamseddine AI and Barada KA: Small bowel tumors: Clinical presentation, prognosis, and outcome in 33 patients in a tertiary care center. J Oncol. 2008(212067)2008.PubMed/NCBI View Article : Google Scholar
27	Lagergren J, Ye W and Ekbom A: Intestinal cancer after cholecystectomy: Is bile involved in carcinogenesis? Gastroenterology. 121:542–547. 2001.PubMed/NCBI View Article : Google Scholar
28	Sakae H, Kanzaki H, Nasu J, Akimoto Y, Matsueda K, Yoshioka M, Nakagawa M, Hori S, Inoue M, Inaba T, et al: The characteristics and outcomes of small bowel adenocarcinoma: A multicentre retrospective observational study. Br J Cancer. 117:1607–1613. 2017.PubMed/NCBI View Article : Google Scholar
29	Zaanan A, Costes L, Gauthier M, Malka D, Locher C, Mitry E, Tougeron D, Lecomte T, Gornet JM, Sobhani I, et al: Chemotherapy of advanced small-bowel adenocarcinoma: A multicenter AGEO study. Ann Oncol. 21:1786–1793. 2010.PubMed/NCBI View Article : Google Scholar
30	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011.PubMed/NCBI View Article : Google Scholar
31	Roxburgh CSD and McMillan DC: Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 6:149–163. 2010.PubMed/NCBI View Article : Google Scholar
32	Howard R, Kanetsky PA and Egan KM: Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer. Sci Rep. 9(19673)2019.PubMed/NCBI View Article : Google Scholar
33	Huffman BM, Patel S, Yadav S, Jin Z and Mahipal A: Lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio independently predict survival in resected small bowel adenocarcinoma. J Clin Oncol. 37 (Suppl 4)(S426)2019.
34	Vano YA, Oudard S, By MA, Têtu P, Thibault C, Aboudagga H, Scotté F and Elaidi R: Optimal cut-off for neutrophil-to-lymphocyte ratio: Fact or Fantasy? A prospective cohort study in metastatic cancer patients. PLoS One. 13(e0195042)2018.PubMed/NCBI View Article : Google Scholar
35	Valero C, Lee M, Hoen D, Weiss K, Kelly DW, Adusumilli PS, Paik PK, Plitas G, Ladanyi M, Postow MA, et al: Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nat Commun. 12(729)2021.PubMed/NCBI View Article : Google Scholar